American Brachytherapy Society - ABS
About the organization
The American Brachytherapy Society was founded in 1978 to provide insight, rationale, and research into the use of brachytherapy in the treatment of both malignant and benign conditions. The organization consists of physicians, physicists, nurses, radiation therapists, trainees in various disciplines and others interested in brachytherapy.
Brachytherapy is used primarily to treat prostate, breast, and cervical cancers and for variety of other cancers including, lung, esophagus, skin cancer, sarcoma, rectum, penis, and ocular melanoma. Because it is much less invasive than surgery, and less disruptive to the patients, brachytherapy offers an effective and meaningful alternative for organ preservation (for example, penis cancer, ocular melanoma, and prostate or rectum cancer). Brachytherapy is an integral part of successful treatment for cervical cancer. When used as a component of treatment, brachytherapy improves survival in patients with advanced disease over the external beam radiating alone. Brachytherapy for prostate cancer improves disease outcomes over external beam radiation, and is a most cost effective treatment for prostate cancer. The American Cancer Society estimates that there will be:
* 288,300 new cases of prostate cancer and 34,700 deaths due to prostate cancer in 2024 ( Since 2014, however, the incidence rate has increased by 3% per year overall and by about 5% per year for advanced-stage prostate cancer). Prostate cancer is the second leading cause of cancer death in men.
* 287,850 new cases of breast cancer and 43,250 deaths due to breast cancer in 2024.
* 12,710 new cases of cervical cancer, and 4,290 deaths due to cervical cancer in 2024.
The mission of the ABS is to benefit patients by providing information directly to the consumer, by promoting the highest possible standards of practice of brachytherapy, and to benefit health care professionals by encouraging improved and continuing education for radiation oncologists and other health care professionals involved in the treatment of cancer. Additionally, the ABS seeks to promote clinical and laboratory research into the frontiers of knowledge of the specialty and to study the socioeconomic aspects of the practice of brachytherapy.
The American Brachytherapy Society was founded in 1978 to provide insight, rationale, and research into the use of brachytherapy in the treatment of both malignant and benign conditions. The organization consists of physicians, physicists, nurses, radiation therapists, trainees in various disciplines and others interested in brachytherapy.
Brachytherapy is used primarily to treat prostate, breast, and cervical cancers and for variety of other cancers including, lung, esophagus, skin cancer, sarcoma, rectum, penis, and ocular melanoma. Because it is much less invasive than surgery, and less disruptive to the patients, brachytherapy offers an effective and meaningful alternative for organ preservation (for example, penis cancer, ocular melanoma, and prostate or rectum cancer). Brachytherapy is an integral part of successful treatment for cervical cancer. When used as a component of treatment, brachytherapy improves survival in patients with advanced disease over the external beam radiating alone. Brachytherapy for prostate cancer improves disease outcomes over external beam radiation, and is a most cost effective treatment for prostate cancer. The American Cancer Society estimates that there will be:
* 288,300 new cases of prostate cancer and 34,700 deaths due to prostate cancer in 2024 ( Since 2014, however, the incidence rate has increased by 3% per year overall and by about 5% per year for advanced-stage prostate cancer). Prostate cancer is the second leading cause of cancer death in men.
* 287,850 new cases of breast cancer and 43,250 deaths due to breast cancer in 2024.
* 12,710 new cases of cervical cancer, and 4,290 deaths due to cervical cancer in 2024.
The mission of the ABS is to benefit patients by providing information directly to the consumer, by promoting the highest possible standards of practice of brachytherapy, and to benefit health care professionals by encouraging improved and continuing education for radiation oncologists and other health care professionals involved in the treatment of cancer. Additionally, the ABS seeks to promote clinical and laboratory research into the frontiers of knowledge of the specialty and to study the socioeconomic aspects of the practice of brachytherapy.
Since 1978
Past events
World Congress of Brachytherapy (ABS 2024) Wednesday, July 10, 2024 - Saturday, July 13, 2024 | National Harbor United States | Brachytherapy
We are delighted to extend an invitation to you for the 2024 World Congress of Brachytherapy, a prestigious event that brings together some of the brightest minds and industry leaders in the field of brachytherapy.